BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20625257)

  • 1. Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
    Guyton JR
    Curr Opin Lipidol; 2010 Aug; 21(4):372-7. PubMed ID: 20625257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinic acid and other therapies for raising high-density lipoprotein.
    Carlson LA
    Curr Opin Cardiol; 2006 Jul; 21(4):336-44. PubMed ID: 16755203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
    Jones PH
    Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of aggressive lipid management.
    Davidson MH; Robinson JG
    J Am Coll Cardiol; 2007 May; 49(17):1753-62. PubMed ID: 17466224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of ezetimibe.
    Cheng AY; Leiter LA
    Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
    Yiu KH; Cheung BM; Tse HF
    Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe: new preparation. A cholesterol-lowering drug with no clinical advantage.
    Prescrire Int; 2004 Oct; 13(73):176-9. PubMed ID: 15499698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive lipid lowering therapy in the era of surrogate endpoints.
    Silverman MG; Blaha MJ; Blumenthal RS
    Cardiol Rev; 2011; 19(1):17-22. PubMed ID: 21135598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezetimibe: a novel option for lowering cholesterol.
    Davidson MH
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
    Meyers CD; Moon YS; Ghanem H; Wong ND
    Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.